Results 61 to 70 of about 60,513 (321)
Abdominal Ultrasonography in Myelofibrosis [PDF]
Acta Radiologica, 1992 The findings at abdominal ultrasonography (US) in 40 patients with myelofibrosis were reviewed, 20 patients being examined at initial diagnosis and 31 at later stages. Splenomegaly was found in 80% at initial diagnosis and in 97% at later stages. The spleen of 2 patients appeared homogeneously hypoechoic and inhomogeneous in one. Focal splenic lesions
T. Siniluoto +4 more
openaire +3 more sources
Management of myelofibrosis after ruxolitinib failure
Annals of Hematology, 2020 Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival.
C. Harrison, N. Schaap, R. Mesa
semanticscholar +1 more source
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]
, 2020 Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M +6 more
core
Next Generation Therapeutics for the Treatment of Myelofibrosis
Cells, 2021 Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis, and a propensity towards transformation to acute leukemia.
D. Tremblay, J. Mascarenhas
semanticscholar +1 more source
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]
, 2016 The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core +2 more sources
Haematologica, 2014 Thrombopoietin-receptor agonists increase platelet counts by stimulating the thrombopoietin receptor. Bone marrow fibrosis has been reported in patients receiving thrombopoietin-receptor agonists.
Waleed Ghanima +6 more
doaj +1 more source
Hematology, 2011 AbstractMyelofibrosis (MF), either primary or arising from previous polycythemia vera (PV) or essential thrombocythemia (ET), is the worst among the chronic myeloproliferative neoplasms in terms of survival and quality of life. Patients with MF have to face several clinical issues that, because of the poor effectiveness of medical therapy, surgery or ...
openaire +5 more sources
The degree of anisocytosis predicts survival in patients with primary myelofibrosis [PDF]
, 2016 Introduction: Red cell distribution width (RDW) provides a quantitative measure of anisocytosis and it is associated with the presence of subclinical systemic inflammation and a poor outcome in a variety of diseases when elevated.
Hariš, Višnja +10 more
core +1 more source
A case of mistaken identity: When lupus masquerades as primary myelofibrosis
SAGE Open Medical Case Reports, 2013 Introduction: Autoimmune myelofibrosis is an uncommon hematologic disease characterized by anemia, bone marrow myelofibrosis, and an autoimmune feature. Myelofibrosis is often associated with other conditions, including infections, nutritional/endocrine ...
Edy Hasrouni +8 more
doaj +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2011 BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Leonardo Caires dos Santos +5 more
doaj +1 more source